The Pennsylvania Senate is voting on SB 866 tomorrow morning, which would classify medetomidine as a Schedule III substance. When the state scheduled Xylazine in 2024, advocates across the country warned that prohibition wouldn't stop the illicit market—it would just force it to adapt, creating an even more volatile and toxic drug supply. Now, lawmakers are preparing to repeat the same mistake, instead of funding the public health infrastructure that is needed.

While medetomidine is a serious and emerging threat, history proves that scheduling alone does not prevent drug supply contamination or reduce overdose deaths. Instead, it forces the illicit market to adapt, introducing newer, unstudied chemical analogs.

The data from a 2025 Philadelphia study on 1,200+ ED encounters is clear:

• Traditional withdrawal protocols are ineffective.

• ICU admissions among affected patients have nearly doubled.

• Severe clinical symptoms (hypertension, extreme agitation) require high-level medical intervention.

Our healthcare providers, researchers, and communities cannot manage a toxic drug supply with criminal statutes. They need enhanced surveillance, immediate clinician education, and robust funding for harm reduction services, including community-based drug checking and education.